Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03916744
Previous Study | Return to List | Next Study

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03916744
Recruitment Status : Recruiting
First Posted : April 16, 2019
Last Update Posted : July 22, 2020
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of GDC-9545 in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: GDC-9545 Procedure: Surgery Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Actual Study Start Date : July 26, 2019
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : July 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: GDC-9545 Dose Level 1 Drug: GDC-9545
GDC-9545 will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Other Name: RG6171

Procedure: Surgery
Breast cancer surgery will take place on Day 15 (+/-2 days).

Experimental: GDC-9545 Dose Level 2 Drug: GDC-9545
GDC-9545 will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Other Name: RG6171

Procedure: Surgery
Breast cancer surgery will take place on Day 15 (+/-2 days).

Experimental: GDC-9545 Dose Level 3 Drug: GDC-9545
GDC-9545 will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Other Name: RG6171

Procedure: Surgery
Breast cancer surgery will take place on Day 15 (+/-2 days).




Primary Outcome Measures :
  1. Change from Baseline in Tumor Cell Proliferation Measured by Ki67 Expression Between Pre- and Post-Treatment Tumor Biopsy Samples [ Time Frame: Baseline and Day 14 or Day 15 ]

Secondary Outcome Measures :
  1. Number of Participants with at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0) [ Time Frame: From Baseline to Day 43 ]
  2. Change from Baseline in Pulse Rate [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
  3. Change from Baseline in Systolic Blood Pressure [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
    Systolic blood pressure will be measured while the participant is in a seated position.

  4. Change from Baseline in Diastolic Blood Pressure [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
    Diastolic blood pressure will be measured while the participant is in a seated position.

  5. Change from Baseline in Body Temperature [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
    Body temperature will be taken by oral or tympanic temperature.

  6. Change from Baseline in Prothrombin Time (PT) [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
  7. Change from Baseline in Activated Partial Thromboplastin Time (aPTT) [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
  8. Change from Baseline in International Normalized Ratio (INR) [ Time Frame: Baseline, Days 1, 8, 15, and 43 ]
  9. Number of Participants with Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v5.0 [ Time Frame: Baseline, Days 1, 8, and 15 ]
    Laboratory parameters for hematology will be measured and compared with a standard reference range. Values outside of the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result will be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment, a medical intervention, or a change in concomitant therapy; or is clinically significant in the investigator's judgment.

  10. Number of Participants with Laboratory Abnormalities in Blood Chemistry Tests by Highest Grade According to NCI-CTCAE v5.0 [ Time Frame: Baseline, Days 1, 8, and 15 ]
    Laboratory parameters for blood chemistry will be measured and compared with a standard reference range. Values outside of the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result will be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment, a medical intervention, or a change in concomitant therapy; or is clinically significant in the investigator's judgment.

  11. Plasma Concentration of GDC-9545 at Steady State [ Time Frame: Day 15 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to comply with the study protocol, in the investigator's judgment
  • Histologically confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice.
  • ER-positive tumor and HER2-negative breast cancer as per local laboratory testing
  • Postmenopausal status
  • Breast cancer eligible for primary surgery
  • Submission of a representative tumor tissue specimen
  • Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (≤)1
  • Adequate organ function

Exclusion Criteria:

  • Diagnosis of inflammatory breast cancer
  • Diagnosis of bilateral breast cancer
  • Concurrent use of hormone replacement therapies
  • Previous systemic or local treatment for the primary breast cancer currently under investigation
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry
  • Current treatment with any systemic anti-cancer therapies
  • Major surgery within 4 weeks prior to enrollment
  • Radiation therapy within 2 weeks prior to enrollment
  • Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
  • Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
  • Known HIV infection
  • Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  • History of allergy to GDC-9545 or any of its excipients
  • Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytic drugs
  • History of documented hemorrhagic diathesis or coagulopathy
  • History or presence of symptomatic bradycardia or sick sinus syndrome
  • Baseline heart rate ≤55 beats per minute (bpm) prior to enrollment
  • History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
  • QT interval corrected through use of Fridericia's formula (QTcF) >470 milliseconds demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well known to prolong the QT interval
  • History or presence of uncontrolled hypothyroidism
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03916744


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: GO40987 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) global-roche-genentech-trials@gene.com

Locations
Show Show 26 study locations
Sponsors and Collaborators
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT03916744    
Other Study ID Numbers: GO40987
2018-003798-85 ( EudraCT Number )
First Posted: April 16, 2019    Key Record Dates
Last Update Posted: July 22, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases